摘要
目的:观察急性髓性白血病(AML)患者Th1/Th2细胞因子变化及使用斯奇康后的变化。方法:用酶联免疫吸附试验(ELISA)测定AML患者血中Th1细胞因子IL-2和INF-γ及Th2细胞因子IL-4和IL-10水平,并与健康对照人群的比较;AML患者在常规治疗的同时,用斯奇康肌肉注射0.3mg/次,2次/周,共18次,同法测定上述细胞因子水平,与治疗前比较。结果:AML患者与健康人群比较,Th1细胞因子IL-2和INF-γ均显著降低(P<0.01),而Th2细胞因子IL-4和IL-10显著增加(P<0.01);与斯奇康治疗前比较,治疗后Th1细胞因子IL-2和INF-γ均增加(P<0.05),而Th2细胞因子IL-4显著降低(P<0.01),IL-10亦有降低,但与治疗前比较差异无显著性(P=0.076)。结论:AML患者存在Th1功能低下而Th2功能相对亢进的免疫失衡状态,斯奇康有改善AML患者上述免疫失衡的功能。
Objective To explore whether acute myeloblastic leukemia(AML) patients have imbalanced Th1/Th2 cytokine levels and to observe the effect of Siqikang on Th1/Th2 cytokines in AML.Methods Peripheral blood were collected from AML patients and healthy control.IL-2,INF-γ,IL-4,IL-10 levels were measured by ELISA methods.Then AML patients were treated with Siqikang(0.3 mg per time,2 times a week,18 times in all),and then IL-2,INF-γ,IL-4,IL-10 levels were measured by ELISA.Results IL-2,INF-γ decreased and IL-4,IL-10...
出处
《实用医技杂志》
2008年第15期1950-1951,共2页
Journal of Practical Medical Techniques